News

An artificial-intelligence-proposed ALS therapy prevented the death of movement-control neurons in a lab and delayed the onset of the disease in an animal model, according to British scientists. The University of Sheffield team said the AI company BenevolentAI suggested the therapy, which has yet to have a name. The drug candidate promotes…

An imbalance between production and degradation of protein in the central nervous system may contribute to amyotrophic lateral sclerosis (ALS), researchers at England’s University of Sheffield suggest. Their study, “Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities?,” appeared in the journal Frontiers in Molecular Neuroscience. It reviewed available data showing that disturbances in…

HVH Precision Analytics presented findings of its big data analysis for earlier diagnosis of ALS (amyotrophic lateral sclerosis) to help clinicians treat patients sooner and allow patients to possibly enroll in clinical trials. HVH’s poster presentation, titled “Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS),” took place at…

Researchers at Ben-Gurion University (BGU) believe that an existing FDA-approved anti-cancer drug, rituximab, could be modified and used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. In lab studies with mice, the therapy restored resident immune cells of the central nervous system, which could indicate…

Data from the open-label extension trial of Radicava (edaravone) in patients with amyotrophic lateral sclerosis (ALS) demonstrated that the treatment continued to provide benefits after 48 weeks of treatment. These findings — presented by researchers from MT Pharma America at the May 18-20 European Network for the Cure…

French biotech company AB Science presented the results of the Phase 3 clinical trial for its lead compound masitinib, which showed effectiveness in improving the functioning of patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The randomized, double-blind clinical trial (NCT02588677) compared the efficacy and…

Mutations in the UBQLN4 gene may contribute to the development of amyotrophic lateral sclerosis (ALS), according to recent research. The study, “A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis,” was published in the journal eLife. Over the years, researchers have identified numerous genes linked to ALS, but the list…

BrainStorm Cell Therapeutics has begun training the cell manufacturing team at City of Hope’s Center for Biomedicine and Genetics to produce NurOwn adult stem cells for a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Los Angeles-based City of Hope will be the clinical…

AB Science will suspend its ongoing masitinib studies in France in patients with cutaneous mastocytosis. However, its studies in patients with amyotrophic lateral sclerosis (ALS) can continue. The pharmaceutical company said it received notice from the French medicines agency Agence Nationale de la Sécurité des Médicaments,…

A gene therapy aimed at strengthening the connection between motor neurons and muscle prevented nerve degeneration and increased the life span of mice with amyotrophic lateral sclerosis (ALS), a study showed. Since researchers believe that neurodegeneration in ALS starts at the junction between nerves and muscle, the findings suggest that…